Eciskafusp Alfa + BCG Medac Strain
Phase 1Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-muscle Invasive Bladder Cancer
Conditions
Non-muscle Invasive Bladder Cancer
Trial Timeline
Jun 15, 2025 → Oct 31, 2030
NCT ID
NCT06816017About Eciskafusp Alfa + BCG Medac Strain
Eciskafusp Alfa + BCG Medac Strain is a phase 1 stage product being developed by Roche for Non-muscle Invasive Bladder Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06816017. Target conditions include Non-muscle Invasive Bladder Cancer.
What happened to similar drugs?
0 of 4 similar drugs in Non-muscle Invasive Bladder Cancer were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06816017 | Phase 1 | Withdrawn |
Competing Products
18 competing products in Non-muscle Invasive Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG) | AstraZeneca | Phase 3 | 44 |
| Durvalumab + BCG | AstraZeneca | Phase 3 | 44 |
| Durvalumab + Monalizumab | AstraZeneca | Phase 2 | 42 |
| Pembrolizumab + BCG | Merck | Phase 3 | 44 |
| Pembrolizumab | Merck | Phase 1/2 | 24 |
| Sacituzumab tirumotecan + Rescue medication + Supportive care measures | Merck | Phase 1/2 | 39 |
| PF-06801591 + Bacillus Calmette-Guerin | Pfizer | Phase 3 | 44 |
| PF-08052667 + Sasanlimab + BCG + PF-02921367 | Pfizer | Phase 1 | 36 |
| BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ) + BCG( 50mg/Instillation) | ImmunityBio | Phase 1/2 | 36 |
| N-803 and BCG + N-803 and Gemcitabine | ImmunityBio | Phase 2 | 39 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 39 |
| Cretostimogene Grenadenorepvec | CG Oncology | Pre-clinical | 27 |
| UGN-301 + UGN-201 + Gemcitabine | UroGen Pharma | Phase 1 | 23 |
| AU-011 | Aura Biosciences | Phase 1 | 26 |
| TARA-002 | Protara Therapeutics | Phase 1 | 19 |
| TARA-002 | Protara Therapeutics | Phase 2 | 32 |
| TARA-002 | Protara Therapeutics | Phase 1 | 19 |
| PD-L1/IDO Peptide Vaccine + Pembrolizumab | IO Biotech | Phase 1 | 26 |